Transcriptional Activation of the Factor VIII Gene in Liver Cell Lines by Interleukin-6

Summary Circulating factor VIII (fVIII) levels increase during inflammation suggesting that fVIII synthesis or secretion is stimulated during acute inflammation. To examine the mechanisms underlying this increase in circulating factor VIII, we have developed a sensitive and reliable semi-quantitative assay for fVIII mRNA utilising competitive reverse transcriptase-polymerase chain reaction (RT-PCR, and used this to study two human liver cell lines, Hep-G2 and Chang Liver cells. These cells were cultured under basal conditions or following treatment with interleukin-1, -2 and 6 (IL-1, -2, and -6). Following 18h culture with IL-6 (maximum concentration 40U/ml), these levels had risen 6 and 9 fold respectively, with no concomitant rise in control RNA levels. The dose responses for both cell types were similar, with an ED50 of 11 U/ml. The time course of this response was also similar in both cell lines with the increase in fVIII mRNA first reaching significance by 3 h, and reaching maximum levels by 12 h. IL-1 and IL-2 had no effect at any of the doses studied. This study provides the first evidence for regulated expression of fVIII in human cell lines, and suggests that increased plasma fVIII levels during the acute phase response may be due to increased expression of fVIII mRNA.

[1]  G. Brownlee,et al.  cis-Acting Elements and Transcription Factors Involved in the Promoter Activity of the Human Factor VIII Gene (*) , 1995, The Journal of Biological Chemistry.

[2]  S. Thompson,et al.  Haemostasis Factors in Angina Pectoris; Relation to Gender, Age and Acute-phase Reaction , 1995, Thrombosis and Haemostasis.

[3]  J. Vandenbroucke,et al.  Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis , 1995, The Lancet.

[4]  J. Cooper,et al.  Factor VIII, ABO blood group and the incidence of ischaemic heart disease , 1994, British journal of haematology.

[5]  Pieter H. Reitsma,et al.  Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.

[6]  Edward G. D. Tuddenham,et al.  The Molecular Genetics of Haemostasis and Its Inherited Disorders , 1994 .

[7]  R. Bertina,et al.  Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study , 1993, The Lancet.

[8]  B. Dahlbäck,et al.  Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[9]  P. Heinrich,et al.  Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level , 1993, Molecular and cellular biology.

[10]  G. Fey,et al.  Synergistic action of interleukin-6 and glucocorticoids is mediated by the interleukin-6 response element of the rat alpha 2 macroglobulin gene , 1992, Molecular and cellular biology.

[11]  D. Bentley,et al.  Direct detection of point mutations by mismatch analysis: application to haemophilia B. , 1989, Nucleic acids research.

[12]  J. Pearson,et al.  von Willebrand factor is an acute phase reactant in man. , 1989, Thrombosis research.

[13]  J. Vandenbroucke,et al.  Mortality and causes of death in Dutch haemophiliacs, 1973–86 , 1989, British journal of haematology.

[14]  L. Ercolani,et al.  Isolation and complete sequence of a functional human glyceraldehyde-3-phosphate dehydrogenase gene. , 1988, The Journal of biological chemistry.

[15]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[16]  R. W. Wright,et al.  Enhancement by N-hydroxysulfosuccinimide of water-soluble carbodiimide-mediated coupling reactions. , 1986, Analytical biochemistry.

[17]  D. Lawrence,et al.  Acquired immunodeficiency syndrome among patients attending hemophilia treatment centers and mortality experience of hemophiliacs in the United States. , 1985, American journal of epidemiology.

[18]  R. Lawn,et al.  Distribution of factor VIII mRNA and antigen in human liver and other tissues , 1985, Nature.

[19]  H. D. Anderson,et al.  FACTOR VIII:C SYNTHESIS IN THE KIDNEY , 1985, The Lancet.

[20]  E. Chen,et al.  Characterization of the human factor VIII gene , 1984, Nature.

[21]  B. Keyt,et al.  Expression of active human factor VIII from recombinant DNA clones , 1984, Nature.

[22]  G. Knutson,et al.  Molecular cloning of a cDNA encoding human antihaemophilic factor , 1984, Nature.

[23]  T. Meade,et al.  Haemostatic changes following surgery. , 1983, Thrombosis research.

[24]  C. Rizza,et al.  Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-80: report on behalf of the directors of haemophilia centres in the United Kingdom. , 1983, British medical journal.

[25]  P. Mannucci,et al.  Alterations of Factor VIII von Willebrand Factor in Clinical Conditions Associated with an Increase in its Plasma Concentration , 1981, British journal of haematology.

[26]  S. Perrin,et al.  8 – COMPETITIVE PCR FOR QUANTITATION OF mRNA , 1990 .

[27]  H. Seliger.  PCR protocols — A guide to methods and applications , 1990 .

[28]  E. Tuddenham.  Factor VIII and haemophilia A. , 1989, Bailliere's clinical haematology.